ESPR on the 120-minute chart is surging with momentum from an FDA approval for a new cholestrol and lipid medication which will be an alternative to the at statin class which has side effects and can cause diabetes. I am familar with a few of the professionals on the science advisory board they are researchers and academics of the highest claiber. The...
OCGN has been a great swing trade after buying bad news. The good news has replaced the bad. Earnings are in three days. Price well below ATH. November earnings were a beat meaning this risky Med Tech penny stock had a lower cash burn than projected. Now legal costs will disappear. Going long with a decent position expecting a better earnings. In law, the...
Stocks that are reporting earnings in 3 to 4 weeks can be monitored for pre-earnings runs. ESPR had momentum runs recently, as marked by the candlestick patterns within the green rectangles in this chart. A shift of sentiment can be seen in the bottoming pattern with Accumulation/Distribution indicators (the area between the blue rectangles). Often, when...
Target price is 11 $ That's enough:) If u have any questions make a comment below
Eyes should be washed, to see things in a different way. Words should be washed To become the wind itself, the rain itself. (Sohrab Sepehri) I shared this watchlist on Friday, October 29th, 2021: I mentioned the Short Squeeze Season has just started..! www.tradingview.com Today 42 out of 50 stocks on this list are positive! (84%), 1 closed at 0,( 2%), and 7...
Market Cap: 370 M Shares Outstanding: 28.2M Average Trading Volume (10 days): 451K Shares Short: 28 M Short Interest(%): 31.4% Days to cover: 15.4 Change in Short Interest: -35 Ownership Breakdown: Institutions: 93.1% General Public: Hedge Funds: 5.6% Individual insiders: 1.3% Sum: 100% Option profile: Total OI: Put Call Ratio:0.63 Put OI: Call OI: Highest...
I think ESPR could start to get interested in this level . - After a long decline from the peak ($ 40) this year, on 27/1/2021, we are now witnessing a consolidation in the price level. - I do not look at fundamental information, only technical data . Indicators : * EMA21 is the purple line * EMA9 is the green line * Consolidation at Slow Stochastic * RSI...
Looks like the pattern is completing, now i expect either a total reversal or a consolidation. All these options are bullish. Comment what you think below. Don't forget to click the like if you do. Thank you.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment. If you...
In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com) Analyst...
This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 96 similar cases where ESPR's Momentum Indicator exceeded 0, and 84 of them led to a successful outcome. Odds of Success: 88%....
I trade charts not fundamentals, this thing had ugly earnings and a Trump rumor of approval of cholesterol-lowering treatment drug make this run 300% in past 2 months. 30.5s is the big resistance, RSI peaking 80 3 times, this thing will correct soon. short 30.5, stop 31.5, don't marry it, it was breaking higher 2 times already, this thing was holding 9 EMA really...